Mirae Asset Global ETFs Holdings
PLX icon

Mirae Asset Global ETFs Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.9K Buy
34,062
+816
+2% +$2.02K ﹤0.01% 2801
2025
Q4 		$59.8K Buy
33,246
+993
+3% +$2.03K ﹤0.01% 2886
2025
Q3 		$71.6K Sell
32,253
-5,822
-15% -$9.48K ﹤0.01% 2817
2025
Q2 		$56.4K Buy
+38,075
New +$77.9K ﹤0.01% 2854
2024
Q3 		– Sell
-34,167
Closed -$40K – 3161
2024
Q2 		$40K Buy
+34,167
New +$40.4K ﹤0.01% 2834

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's PLX Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Protalix BioTherapeutics (PLX) stake by 2.5% in Q1 2026, buying an estimated $2.02K and bringing the position to 34,062 shares worth $73.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2801.

Mirae Asset Global ETFs Holdings first reported a position in PLX in Q2 2024 and has held it in 5 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 34,062 shares of Protalix BioTherapeutics worth $73.9K as of Q1 2026.
  • Mirae Asset Global ETFs Holdings bought 816 Protalix BioTherapeutics shares in Q1 2026, an estimated $2.02K.
  • Protalix BioTherapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2801 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 5 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.